Neuropeptide Y—Graphene Oxide Complexes Inhibit Amygdala NPY‐Receptor Expressing Glutamatergic Pathways and Selectively Remove Aversive Memory In Vivo
Abstract
Therapeutic needs to modulate brain circuits highlight graphene-based materials (GBMs) as an emerging tool to engineer specific interventions to treat neuro-diseases. In this context, graphene oxide (GO) nanosheets offer new drug delivery strategies to reach neural cells and signaling networks selectively. To complex and transport neuropeptide Y (NPY), GO was engineered as GO:NPY, and its activity was investigated in regulating excitatory neurotransmission in NPY-positive synaptic pathways, when delivered to the amygdala, a structure mediating fear memory responses. First, it was shown that in vitro GO:NPY specifically and selectively inhibited glutamate release and suppressed synaptic enhancement via NPY receptors. In a rat model of anxiety disorder, when injected into the amygdala, GO:NPY suppressed contextual fear memory responses via activation of NPY receptors in specific synaptic pathways. This easy-to-tune GBM-based nanoplatforms promise advances in co-delivery vectors preserving the synaptic specificity needed for treating specific pathological conditions.
Related
- From neuropeptide and receptor annotation to ligand-receptor pairing: a sequence- and structure-based framework for mapping the neuropeptide-receptor interactome in Gryllus bimaculatus
- From Metabolite to Signalling: Evolutionary Assembly of the Glutamatergic System Across Metazoans
- Medial septum glutamatergic neurons support speed coding and grid cell spatial stability in the medial entorhinal cortex
- Dietary vitamin B5 positively regulates intestinal neuropeptide secretion in C. elegans
- Glutamatergic Neurons in caudal Pontine Reticular Nucleus (PRNc) Mediate Backward Locomotion in mice
BibTeX
@article{pati2026neuropeptide,
title = {{Neuropeptide Y—Graphene Oxide Complexes Inhibit Amygdala NPY‐Receptor Expressing Glutamatergic Pathways and Selectively Remove Aversive Memory In Vivo}},
author = {Elisa Pati and Audrey Franceschi Biagioni and Raffaele Casani and Luis M Arellano and Tommaso Battisti and Gloria Garcia‐ortega and Neus Lozano and Alberto Bianco and Kostas Kostarelos and Laura Ballerini and Giada Cellot},
journal = {Advanced Science},
year = {2026},
month = jul,
doi = {10.1002/advs.76608},
url = {https://hal.science/hal-05769758v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Neuropeptide Y—Graphene Oxide Complexes Inhibit Amygdala NPY‐Receptor Expressing Glutamatergic Pathways and Selectively Remove Aversive Memory In Vivo
AU - Elisa Pati
AU - Audrey Franceschi Biagioni
AU - Raffaele Casani
AU - Luis M Arellano
AU - Tommaso Battisti
AU - Gloria Garcia‐ortega
AU - Neus Lozano
AU - Alberto Bianco
AU - Kostas Kostarelos
AU - Laura Ballerini
AU - Giada Cellot
PY - 2026
DA - 2026/07/31
JO - Advanced Science
DO - 10.1002/advs.76608
UR - https://hal.science/hal-05769758v1
AB - Therapeutic needs to modulate brain circuits highlight graphene-based materials (GBMs) as an emerging tool to engineer specific interventions to treat neuro-diseases. In this context, graphene oxide (GO) nanosheets offer new drug delivery strategies to reach neural cells and signaling networks selectively. To complex and transport neuropeptide Y (NPY), GO was engineered as GO:NPY, and its activity was investigated in regulating excitatory neurotransmission in NPY-positive synaptic pathways, when delivered to the amygdala, a structure mediating fear memory responses. First, it was shown that in vitro GO:NPY specifically and selectively inhibited glutamate release and suppressed synaptic enhancement via NPY receptors. In a rat model of anxiety disorder, when injected into the amygdala, GO:NPY suppressed contextual fear memory responses via activation of NPY receptors in specific synaptic pathways. This easy-to-tune GBM-based nanoplatforms promise advances in co-delivery vectors preserving the synaptic specificity needed for treating specific pathological conditions.
SN - 2198-3844
ER -